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Background: The polyherbal eye drop (ItoneTM) is a mixture of aqueous distillates of nineteen traditionally used
ingredients that sum up to impart potency to the formulation and make it a useful adjunct in various ocular
pathologies. However, as there have been no controlled experimental studies accounting to the above claim,
therefore, the present study was designed to evaluate the polyherbal formulation (PHF) for antiangiogenic, anti-
inflammatory, anticataract, antioxidant and cytotoxicity in addition to the evaluation of intraocular penetration of PHF
in rabbit eyes using LC-MS/MS.
Materials and methods: Antiangiogenic activity of the PHF was evaluated using in ovo chick chorio-allantoic
membrane (CAM) assay and in vivo cautery induced corneal neovascularization assay in rats. Anticataract potential
was evaluated using steroid induced cataract in developing chick embryos, sodium selenite induced cataract in rat
pups and galactose induced cataract in rats. The antioxidant activity was evaluated using di-phenyl picryl hydrazyl
(DPPH) radical scavenging assay. Anti-inflammatory activity was evaluated in vitro using inhibition of LTB4 formation
in human WBCs and in vivo using carrageenan induced paw edema assay in rats. The cytotoxicity was evaluated
against HeLa cancer cell lines using (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
Furthermore evaluation of the intraocular penetration of the PHF was carried out in rabbit eyes via aqueous humor
paracentesis and further analysis using LC-MS/MS.
Results: PHF significantly inhibited VEGF induced proliferation of new blood vessels in CAM assay and inhibited the
cautery induced corneal neovascularization in rats. Additionally, PHF showed noticeable delay in the progression of
cataract in the selenite and galactose induced cataract models whereby the PHF treated lenses were graded for
stages II and III respectively. However, the PHF did not show any anticataract activity in the hydrocortisone induced
cataract model. Moreover, PHF exhibited anti-inflammatory activity whereby it showed 39.34% inhibition of LTB4
formation and significantly inhibited carrageenan induced paw edema in rats. Eight compounds of PHF viz.
camphor, casticin, curcumin-II, quercetin, rosmarinic acid, γ-terpinene, β-pinene and dipentene exhibited
transcorneal penetration in rabbit eyes.
Conclusion: The significant antiangiogenic and anti-inflammatory activities evinced by the PHF merits further
investigation for ocular neovascular and inflammatory diseases in humans.
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The extracts of herbal products and Ayurvedic, Siddha
and Unani formulations are mixtures of at least partially
uncharacterized constituents. It is claimed that such a
mixture provides a therapeutic advantage, since the un-
known constituents may be additive or synergistic in ac-
tion or may produce a balance to counteract adverse
effects of any one constituent. This may provide more
efficacy than the known constituent used alone. Thus,
purification of the medicines is not required as it may
lead to loss of the advantages provided by the mixture
[1]. An ayurvedic proprietary polyherbal eye drop (Itone™)
developed on the basis of ayurvedic principles have been
available for the last 25 years in Indian Market and has
been recognized to have medicinal value for various ocu-
lar ailments. The polyherbal formulation (Itone™) consists
of a fixed combination of the aqueous distillates of nineteen
traditionally used ingredients including Azadirachta indica
(nimba-5%), Moringa pterygosperma (sobhanjana-5%),
Eclipta alba (bhringaraj-5%), Boerhaavia diffusa (punar-
nava-7.5%), Carum copticum (yamani-2%), Terminalia
chebula (haritaki-5%), Terminalia belerica (vibhitaka-5%),
Emblica officinalis (dhatriphala-5%), Santalum album (swet
chandan-5%), mukta (pearl-1%), Ocimum sanctum (tulsi
patra-5%), Vitex negundo (nirgundi-5%), Curcuma longa
(haridra-5%),Mentha piperata (menthol-2%), Cinnamomum
camphora (camphor-3%), Amomum subulatum (ela-5%),
Rosa centifolia (satapatri-7.5%), saindhava laban (rock
salt-2%) and madhu (honey-10%). It has been reported
to be a useful adjunct in various ocular diseases like
conjunctivitis, trachoma, blepharitis, keratitis, corneal
ulcers etc. It has been reported to maintain the visual
acuity and helpful in computer vision syndrome [2,3].
Several clinical studies are available appreciating the
effect of Itone™ in various ocular pathologies. However,
controlled experimental studies are not available to sub-
stantiate the claim. Therefore, the present study was car-
ried out to systematically evaluate the above polyherbal
formulation (PHF) for several ocular indications using
contemporary technologies and experimental models to
explore antiangiogenic, anticataract, anti-inflammatory,
cytotoxicity and antioxidant properties. The above PHF
was also subjected for the evaluation of its intraocular
penetration after topical application in rabbits. These
approaches are expected to increase the modern applica-




Vascular Endothelial Growth Factor (VEGF) and MTT
were purchased from Sigma-Aldrich, USA. Dulbecco’s
Modified Eagle Medium (DMEM) was purchased from
Invitrogen, India. Hydrocortisone sodium succinateinjection was purchased from Alkem laboratories Ltd.,
Mumbai, India. Sodium selenite was purchased from
Loba chemie, India. Riboflavin was purchased from
Sisco Research Laboratories Pvt. Ltd., Mumbai, India.
Galactose was purchased from Spectrochem Pvt. Ltd.,
Mumbai, India. The preservative free PHF (Itone™ eye
drops, Batch No - 2142) were provided by Dey’s Medical
Stores, Kolkata, India. All the other reagents were of
analytical grade and were used without further purification.
All study protocols were approved by standing Institu-
tional Animal Ethics Committee (IAEC) of All India
Institute of Medical Sciences (AIIMS), New Delhi, India.
All animal experiments were done in accordance with
guidelines of Association for Research in Vision and
Ophthalmology (ARVO).
Evaluation of antiangiogenic activity of the PHF
Chick Chorio-Allantoic Membrane (CAM) assay
The CAM assay was performed as per the procedure
described by Ribatti et al., 1997 [4] with slight modifica-
tions. Briefly, fresh fertile white leghorn chick eggs were
purchased from Kegg Farm (Gurgaon, Haryana, India)
and further placed in a humidified incubator at 36 ± 2°C.
On the third day of incubation, a hole was drilled on
the egg shell and 2–3 ml of albumin was withdrawn
aseptically. The hole was sealed using sterile parafilm
and eggs were re-subjected for incubation. On seventh
day, a suitable window was opened and VEGF (50 ng)
in ovalbumin coated coverslips of 12 mm diameter
(with or without test substance) were placed over the
chorio-allantoic membrane. Coverslips coated only
with ovalbumin, ovalbumin with VEGF, ovalbumin
with VEGF and thalidomide (10 μg), ovalbumin with
VEGF and PHF (50 μl) served as normal, control, positive
control and test respectively. A minimum of 8 eggs were
used per group. The windows were further sealed with
sterile parafilm and eggs were reincubated for further
period up till twelfth day. On the day 12, the blood vessels
grown under the coverslip area were digitally photographed
using a sensitive CCD camera directly attached to the
computer using graphic user interface. The blood vessel
areas were analysed using Aphelion Developer Image
Analysis Software (Adcis, France).
Corneal neovascularization assay
Corneal neovascularization was induced by chemical
cauterization, using the technique described by Mahoney
& Waterbury,1985 [5]. One cornea of each rat was cau-
terized by pressing an applicator stick (with a diameter
of 1.5 mm) coated with 75% silver nitrate / 25% potas-
sium nitrate on the centre of the cornea for 5 sec while
the animal was deeply anesthetized with sodium pento-
barbitone. To increase the reproducibility of the injuries,
the same investigator cauterized all animals. Following
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tial bias in the degree of injury within the different groups.
Rats were randomly divided into three groups (n = 6) viz.
sham, positive control (bevacizumab 1.25 mg/ml) and
PHF treated. 20 μl of test was applied topically to each
cauterized cornea three times per day for 5 days starting
from the day of cauterization. The first treatment
with each medication was started approximately 30 min
after cauterization. The corneal neovascularization was
assessed on day 6 after cauterization whereby the corneas
of all rats were subjected for photography using CCD
camera. The photographs were further subjected for
quantification of corneal neovascularization using the
Aphelion Dev. image analysis software (Adcis, France).
Evaluation of PHF for its cytotoxicity
MTT assay
The HeLa cancer cell lines (No. 25) were obtained from
National Centre for Cell Science (NCCS), Pune, India
and suspended in 2.0 ml of DMEM (10% Fetal Bovine
Serum). Cell count was adjusted to 5 × 104 cells/ml.
100 μl of this cell suspension was plated in each well of
96-well ELISA plate. Plated cells were incubated in a
CO2 incubator (5% CO2, 37°C) for 16 h, after which the
media was removed from wells and fresh DMEM media
containing 50 μl PHF was added in triplicates followed
by further incubation for 24 h. After 24 h, DMEM media
was removed and 100 μl of MTT (1 mg/ml) was added
to each well followed by incubation for 3 h in CO2 incu-
bator. After 3 h, media containing MTT was removed
and 100 μl of DMSO was added to each well to dissolve
the formazan crystals. Absorbance was taken at 570 nm
and 655 nm.
Evaluation of anticataract potential of PHF
Hydrocortisone induced cataract in developing chick
embryos
The procedure previously standardized in our laboratory
[6] was used for this experiment. Briefly, ten days old
White leghorn chick eggs were procured from Kegg
Farm (Gurgaon, Haryana, India). The eggs were ran-
domly divided into three groups (n = 8) namely normal
(saline treated), control and PHF treated respectively. All
the eggs were incubated in a humidified incubator at
36 ± 2°C. On 15th day, a hole was drilled in the eggshell
over the air sac. Control and test groups received hydro-
cortisone (0.25 μM/0.1 ml) injected through the hole to
induce cataract where as normal group received 0.1 ml
of normal saline. The puncture was sealed with an adhe-
sive tape and eggs were re-incubated. Control and test
groups received 0.1 ml of normal saline and PHF at 3,
10 and 20 h after hydrocortisone injection respectively.
After 48 h of the hydrocortisone injection the groups
were sacrificed and the eyes were enucleated. The lenseswere dissected out and were subjected for grading by
two independent observers who were not aware of the
treatment.
For the evaluation of lens, original grading of Nishigori
et al., 1982 [7] was used, stage 1 - lens is clear and indis-
tinguishable from normal (no cataract), stage 2 - faint
opaque ring between the cortical region and nuclear
region, stage 3 - distinct opaque ring between both the
regions, stage 4 - lens has a pin hole size of clear area in
opaque nucleus and stage 5 - opaque nucleus.
Selenite induced cataract model
Wistar female albino rats along with pups (6 days post-
natal) were housed together. Nursing mother was fed
with normal diet and water ad libitum. Two groups hav-
ing mother and pups were divided. The pups of each rat
were divided into two groups namely control and PHF
treated and each group consisted of 6 pups respectively.
The rat pups of the control and treated group were
given sodium selenite at the dose of 25 μM/kg subcuta-
neously on the 9th postnatal day. Treated group received
PHF subcutaneously in the volume of 0.05 ml from the
seventh postnatal day to sixteenth day. The eyes were
subjected for torchlight and slit lamp examination on
the sixteenth postnatal day and compared with control
for the presence and absence of nuclear cataract [8].
In vivo galactose induced cataract in rats
Wistar albino rats of either sex weighing 80–100 g were
fed with 30% galactose diet with water ad libitum for
28 days. The rats were divided equally into two groups
of control and test, each consisting of 5 animals. Test
group was instilled with PHF amounting to 20 μl three
times a day and control animals received saline. Each
eye was evaluated for the presence of cataract and was
graded by Sippel’s method [9] using slit lamp on 7, 14,
21 and 28th day.
Grading of lenses Two independent observers those
who were not aware of the treatment evaluated the
stages of cataract using slit lamp biomicroscopy in rat
eyes and mean of their grading was considered for
further comparisons. The lenses were graded using the
Sipple’s scale, Stage 1 - Clear lens, Stage 2 - Peripheral
vacuoles, Stage 3 - Irregular peripheral vacuoles with the
involvement of lens cortex, Stage 4 - Irregular opacity of
lens and Stage 5 - Pronounced opacity.
Evaluation of the PHF for its antioxidant activity
DPPH radical scavenging assay
The free radical scavenging activity of PHF was mea-
sured in term of hydrogen donating or radical scaven-
ging ability using the stable radical DPPH [10]. Briefly,
1.0 ml of 0.1 mM solution of DPPH in ethanol was
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and 30 min later, the absorbance was measured at
517 nm. Sodium ascorbate was used as a positive control
and deionized water served as control. Percentage rad-
ical scavenging activity (%RSA) was calculated by follow-
ing equation:
%RSA ¼ Abscontrol  Abstestð Þ=Abscontrol100
Abscontrol is the absorbance of control in presence of
deionized water without test and Abstest is the absorb-
ance in presence of PHF or Sodium ascorbate. The anti-
oxidant activity was expressed as IC50 (concentration
(μg/ml) of the test that inhibited the formation of DPPH
radicals by 50%).
Evaluation of PHF for its anti-inflammatory activity
Carrageenan induced paw edema
Overnight fasted Wistar albino rats (n = 6) of either sex
(100–150 g) were divided into control (saline treated),
positive control (diclofenac 5 mg/kg bodyweight treated)
and experimental (4 ml/kg PHF treated) groups. After
one hour of intraperitoneal drug administration, paw
edema was induced by single injection of 0.1 ml of 1%
carrageenan injected intradermally on the plantar side of
the right hind paw. Paw volumes were measured using a
digital plethysmometer (Inco, Haryana) immediately be-
fore the injection of carrageenan and at hourly intervals
for 4 h thereafter. The volume of edema was expressed
for each rat as the difference before and after the
injection of carrageenan. The percent inhibition of paw
edema was calculated by following equation:
%Inhibition ¼ Vc–Vt=Vc100
Vc is the paw volume of control that received saline
and Vt is paw volume of test that received PHF or
Diclofenac.
LeukotrieneB4 (LTB4) inhibition assay
Fresh buffy coat was obtained from hospital blood bank
and subjected for WBC separation using HiSep (Hi-media,
Mumbai) and diluted with equal volume of Hank’s
balanced salt solution. The metabolism of endogenously
bound arachidonic acid to LTB4 was measured in a total
volume of 0.4 ml of the cell suspension at 37°C. The
reaction tubes were containing 20 μg arachidonic acid
and the investigational drugs (PHF and zileuton). After
45 min pre-incubation the reaction was started by
addition of 20 μg of calcium ionophore and 2 μg of
glutathione. After 15 min the reaction was stopped with
40 μl of 0.1 M HCl. After centrifugation for 2 min ali-
quots of the supernatant were subjected to LC-MS/MS
estimation of LTB4.Hypersil GOLD column (50 mm × 2.1 mm, 1.9 μm,
Thermo, Waltham, MA, USA) with a gradient system of
acetonitrile with 0.1% formic acid and water with 0.1%
formic acid was used for chromatographic separation.
The gradient was started with 80:20 water/acetonitrile
and reached to 30:70 in 3 min and first line condition
was achieved over a period of 2 min. Flow rate was
maintained at 0.5 ml/min.
Tandem Mass spectrometric detection of analytes and
internal standard (IS) was carried out with an electro-
spray ionization (ESI) source operated in the negative
mode. Multiple Reaction Monitoring (MRM) mode was
performed for quantification. 335.2 m/z was selected as
precursor ion (Q1) whereas 317.2 m/z and 195.1 m/z
(Q3) were selected as product ion for LTB4. Optimized
compound dependent parameters were Declustering Po-
tential (DP) - 76, Entrance Potential (EP) - 10, Collision
Energy (CE) - 20 and Collision Cell Exit Potential (CXP)
- 8. Probenecid was selected as an IS with 283.91 m/z
(Q1) and 240 m/z (Q3).
Evaluation of intraocular penetration of PHF
New Zealand Albino Rabbits (n = 4) of either sex weigh-
ing 2–2.5 kg body weight were used for this study.
Briefly 50 μl of PHF was instilled after each 10 min for
1 h into the cul-de-sac of the rabbit eyes. After comple-
tion of dosing, eyes were thoroughly washed with nor-
mal saline and aqueous humor was aspirated at 2 h via
paracentesis. Briefly, eyes were anaesthetized by instilling
4% lidocaine and 70–100 μl of aqueous humor was with-
drawn with the help of 30 G sterile hypodermic needle.
All the samples were stored at −70°C until analysis by
LC-MS/MS.
For the detection of compounds in PHF, information
dependent acquisition (IDA) method using a hybrid sys-
tem of Ultra High Performance Liquid Chromatography
(UHPLC) coupled with Mass Spectrometry (LC-MS/MS)
was used.
UHPLC (Accela, Thermo Surveyor system, Thermo
Electron Corp, Waltham, MA, USA) was equipped with
a quaternary pump connected to an online degasser and
photodiode array (PDA) coupled with triple quadrupole
mass spectrometer (4000 Q-Trap, AB/MDS Sciex, Foster
City, CA, USA). LunaW column (250 mm × 4.6 mm,
5 μm, Phenomenex, USA) with a linear gradient system
of water with 0.1% formic acid and acetonitrile with
0.1% formic acid was used for chromatographic separ-
ation. Gradient was started with 10% organic mobile
phase and reached to 100% with 18% increase in each
5 min.
Tandem Mass spectrometric detection was carried out
on an Applied Bio Systems 4000 triple quadrapole
instrument (ABS Biosystems, Foster City CA, USA)
equipped with an ESI source that operated in the
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atomic mass unit (amu), IDA scanning was done at a
speed of 1000 Da/s with Enhanced Mass Scan (EMS).
Chromatogram for PHF obtained from IDA scan was
screened for the masses available in literature.
The analytes which were found to be present in IDA
scan for PHF were further confirmed by observing
their fragmentation patterns using MRM mode in LC-
MS/MS. For MRM, all compounds were optimized for
their fragmentation patterns and compound dependent
parameters and subsequent separation of compounds
was achieved using PurospherW STAR RP-18 (55 mm ×
4 mm, 3 μm, Merck, Darmstadt, Germany) column with
guard. For chromatographic separation a linear gradient
of water with 0.1% formic acid and acetonitrile with
0.1% formic acid was used in a starting ratio of 90%
acetonitrile. The gradient reached to 100% organic phase
with an increment of 1% in 1 min.
The aqueous humor samples were also subjected for
the same optimized MRM conditions in LC-MS/MS.
For this 50 μl of thawed aqueous humor samples
were processed by adding 50 μl of extraction solvent
[90% acetonitrile with 250 ng of sulfadimethoxine (IS)].
All the samples were then vortexed for 1 min and
centrifuged at 3600 g for 10 min and further subjected
for analysis.Figure 1 Effect of PHF on the chick chorio-allantoic membrane obser
the Chorio-Allantoic Membrane (CAM) for different groups. A. Normal. B. T
VEGF 50 ng. D. Treated with 50 μl of PHF along with VEGF 50 ng.Statistical analysis
All the data are presented as mean ± SEM and statistical
significance was calculated using Sigma plot version 11.
For CAM and corneal neovascularization assay, groups
were compared using unpaired student-t test. In carra-
geenan induced rat paw edema method different groups




VEGF at a concentration of 50 ng was found to signifi-
cantly induce the proliferation of new blood vessels in
comparison to the normal group. PHF showed signifi-
cant antiangiogenic activity (Figure 1) as it profoundly
inhibited the VEGF induced proliferation of new blood
vessels when compared to the VEGF control group
(Table 1). Thalidomide was used as a positive control for
the study whereby it was found to significantly inhibit
the VEGF induced proliferation of new blood vessels at a
concentration of 10 μg.
Cautery induced corneal neovascularization
There was no corneal neovascularization observed in the
normal (uncauterized) corneas. The PHF group showed
significant antiangiogenic activity in the cautery inducedved on day 12 of incubation. Photographs showing blood vessels on
reated with VEGF 50 ng. C. Treated with Thalidomide 10 μg along with
Table 1 Representation of vessel area per coverslip in
CAM assay
GROUP VESSEL AREA / COVERSLIP
(mm×mm)
Normal 39.67 ± 0.38
Control (VEGF 50 ng) 90.35 ± 0.33
Thalidomide 10 μg + VEGF 50 ng 27.65 ± 0.31
PHF 50 μl + VEGF 50 ng 48.06 ± 0.4*
Data are presented as mean ± SEM (n = 8). *p ≤ 0.001 vs Control Group.
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to the sham treated group which showed considerable
neovascularization in the cornea of rat eyes (Table 2). The
positive control (bevacizumab) was observed to signifi-
cantly inhibit the cautery induced corneal neovasculariza-
tion at a concentration of 1.25 mg/ml.
Cytotoxicity
The LD50 for taxol was found to be 5.05 μg/ml whereas
the PHF did not exhibit any cytotoxicity against the
HeLa cancer cell lines.
Hydrocortisone induced chick cataract
The normal (untreated by hydrocortisone) group evinced
no development of cataract and control group was gradedFigure 2 Effect of PHF in cautery induced corneal neovascularization
A. Cauterized cornea. B. Sham treated cornea. C. Bevacizumab 1.25 mg/mlfor stage V (nuclear opacity). In this model PHF showed
only a slight protection against cataract as compared to
the control group and was graded for stage IV cataract
(Figure 3).In vivo selenite induced oxidative model of cataract
The PHF treated group showed significant protection as
compared to the control group. In the control group,
100% eyes showed cataract development and were
graded for stage IV. Whereas, the eyes treated with PHF
showed noticeable delay in the progression of cataract
and were graded for stage II. The observations clearly
demonstrated the potential of the PHF in delaying the
progression of cataract in comparison to the control
group.In vivo galactose induced cataract in rats
At the end of 4 weeks (after galactose feeding) the con-
trol group showed significant development of cataract.
The lenses in control group depicted stages V respect-
ively, as per Sipple’s gradings. The PHF treated lenses
showed slight delay in the development of cataract and
were graded for stage III (Figure 4).in rats. Photographs showing rat corneas for different groups.
treated cornea. D. PHF 50 μl treated cornea.
Table 2 Vessel area in the cauterized corneas of different
groups
GROUP AREA OF CORNEAL BLOOD VESSELS
(mm×mm)




PHF (20 μl) 12.48 ± 0.37*
Data presented as Mean ± SEM (n = 6). *p ≤ 0.001 vs Sham treatment.
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The IC50 of the standard (sodium ascorbate) was found
to be 5.9 μg/ml. comparatively, the PHF did not show
any significant antioxidant activity and the percentage
radical scavenging activity up to the maximum of
1.25 ml of PHF was found to be only 26.6%.
Carrageenan induced paw edema
Diclofenac showed maximum inhibition of paw edema
(63.6%) after 3 h of its induction via carrageenan. Com-
paratively, the PHF showed maximum inhibition of paw
edema (51.8%) after 3 h (Table 3).
In vitro LTB4 inhibition assay
In the in vitro method involving LTB4 inhibition from
human WBC, zileuton was used as a positive control that
showed 100% inhibition of LTB4 formation at the tested
concentration of 20 μg as compared to untreated control.
Among various volumes tried, test group received 20 μl
of PHF showed 40% inhibition of LTB4 formation as
compared to the control group (Figure 5).
Intraocular penetration of PHF
PHF tested by IDA protocol showed presence of ar-
turmerone, camphor, casticin, curcumin-I, curcumin-II,
iso-orientin, luteolin, menthol, quercetin, rosmarinicFigure 3 The effect of PHF on lenses in the hydrocortisone induced c
stages of cataract. A: Stage 1: Normal group B: Stage 4: PHF treated group.acid, thymol, wedelolactone, sabinene, γ-terpinene, β-
pinene, dipentene. These compounds were further con-
firmed by MRM.
Aqueous humor subjected for optimized MRM for
PHF showed presence of camphor, casticin, curcumin-II,
quercetin, rosmarinic acid, γ-terpinene, β-pinene and
dipentene (Figure 6).
Discussion
The polyherbal eye drop (Itone™) is a sterile topical for-
mulation that has been found to have pH 5.1 and is
hypo-osmolar in nature. It has been claimed to protect
eyes from continuous strains, glares of light and various
forms of pollution upon its instillation. It has also been
indicated as an adjunct in various ophthalmic conditions
like conjunctivitis, trachoma, blepharitis, keratitis, cor-
neal ulcers, lentricular opacity, myopia, hypermetropia
and dacrocystitis [11]. Experiments so far evaluated
using PHF showed several properties viz., lack of any
acute, subacute CNS toxicity after oral administration in
animals, lack of ocular irritancy in rabbits and promin-
ent antimicrobial activity against Staphylococcus aureus
and Klebsiella pneumoniae [11]. In clinical studies, the
PHF under study has been found to be effective in trach-
oma, chronic conjunctivitis [12], subjective improvement
in refractory errors [13] healing capacity in allergic con-
junctivitis [13], viral conjunctivitis [14,15] and computer
vision syndrome [2]. Although, enough literature is avail-
able regarding the above therapeutic uses for the PHF, no
systematic study is available to substantiate the claim using
controlled experiments. Therefore, the present study was
conducted to evaluate antiangiogenic, anticataract, anti-in-
flammatory, antioxidant and cytotoxic potential of the PHF
using several experimental models. As PHF under study
was also reported to provide relief from iridocyclitis, early
senile lenticular opacity and IOP lowering effect inataract model in chicks. Photographs showing lenses in different
Figure 4 The effect of polyherbal formulation on lenses in the galactose induced cataract model in rats. Photographs showing lenses in
different stages of cataract: A: Stage 5: Control group B: Stage 3: PHF group.
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Therefore, this study was extended to evaluate the intraocu-
lar penetration in the rabbit eyes upon topical application
using liquid chromatography coupled tandem mass
spectrometry.
Ocular angiogenesis is responsible for the majority of ir-
reversible blindness in the developed world. This debilitat-
ing complication affects all age groups and characterizes
such diverse and widespread diseases as trachoma, retin-
opathy of prematurity, diabetic retinopathy, neovascular
glaucoma and age-related macular degeneration [16].
Angiogenesis is a tightly regulated process involving the
development of new blood vessels from pre-existing blood
vessels. During development and normal physiological
processes such as wound healing and the menstrual cycle,
angiogenesis is regulated by endogenous activators and
inhibitors [17,18]. In pathological settings, such as age-
related macular degeneration, rheumatoid arthritis, dia-
betic retinopathy and tumor growth and metastasis,
angiogenesis is critical for disease progression [17,19].
The present study evaluated the antiangiogenic poten-
tial of a PHF using the in ovo chick CAM assay – an
assay that is capable of evaluating the action of testTable 3 Effect of PHF and diclofenac on carrageenan





Control 1.1 ± 0.02 -
Diclofenac (5 mg/kg
body weight)
0.4 ± 0.02a 63.63
PHF (4 ml/kg body
weight)
0.53 ± 0.02a 51.8
Data are presented as mean ± SEM (n = 6). aP ≤ 0.001 when compared with
control.substance (plant extracts) on angiogenesis [20]. For this
assay, VEGF 50 ng was used as an angiogenesis stimula-
tor and was found to significantly induce proliferation of
new blood vessels as compared to the normal group. In
this assay, PHF was found to have significant antiangio-
genic potential at the studied concentration thereby
inhibiting VEGF induced proliferation of new blood
vessels.
In order to understand the in vivo significane of the
above finding an animal study was carried out using
chemical cautery induced corneal neovascularization in
rats. Neovascularization has been reported as an import-
ant pathologic event during the corneal wound healing
process [21] and VEGF has been reported to play an im-
portant role in its pathogenesis [22]. Neovascularization
of cornea may cause loss of corneal transperancy and
thereby leads to loss of vision [23]. In the present study,
topical instillation of the PHF was found to significantly
inhibit chemical cautery induced corneal neovasculariza-
tion as compared to sham treated control. In this assay,
bevacizumab, a known anti-VEGF monoclonal antibody
was used as a positive control that showed 67% inhib-
ition of the cautery induced corneal neovascularization
in comparison to the sham treated group that showed
noticeable corneal neovascularization in the cauterized
eyes. The antiangiogenic activity observed for PHF was
found to be only 18%, thereby concluding that the
antiangiogenic activity observed with PHF is mild in
comparison to the potential antiangiogenic compounds
like bevacizumab.
Interestingly, the present study revealed that the PHF
was found to be safe upon application to the chick
embryos and there was no toxicity found. Chorio-
allantoic membrane assay is also a well recognized
Figure 5 LC-MS/MS chromatograms showing levels of LTB4 in human WBC’s. A: Control group, B: PHF treated.
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http://www.biomedcentral.com/1472-6882/13/1method to study ocular toxicity of drugs [24]. It is
assumed as acute irritating effects on the small blood
vessels and protein membrane are similar to effect
induced by same chemical in the eye [25]. Further to the
above observation, lack of any cytotoxicity of the studied
PHF was confirmed in HeLa cell lines using MTT assay.
In this cytotoxicity assay paclitaxel was used as positive
control. This study further confirms lack of any ocular
toxicity oberved in majority of the above studies [11].
Inflammatory stimulus is a factor responsible for
micro-vascular gowth (neovascularization) during the
active pro-angiogenic phase. Therefore, capillary regres-
sion is of interest from a clinical perspective [26]. Thera-
peutic strateties for reducing the vacular growth has
been well accepted as a therapeutic option for pathologic
angiogenesis in tumors, eye diseases, and inflammation.
Anti-inflammatory compounds like COX-2 inhibitors
and steroids are reported to have anti-angiogenicpotential [27,28]. Therefore, the present study was
extended to carry out anti-inflammatory property of the
PHF in the carageenan induced paw edema model of
inflammation.
Inflammation is a normal protective responce to tissue
injury caused by physical trauma, noxious chemical or
microbial agents and involves release of various inflam-
matory mediators such as leukotrienes and prostaglan-
dins [29-31]. In the present study, anti-inflammatory
activity of PHF was tested using carrageenan induced
paw edema assay which has been used since time as a
standard technique for the screening of anti-inflammatory
activity of several herbal extracts [32,33]. PHF was
observed to possess noticeable anti-inflammatory activity,
though the activity was comparatively lesser than the posi-
tive control (diclofenac). Furthermore, PHF was evaluated
for its inhibitory effect on the formation of LTB4 in human
WBCs. LTB4 is a known potent inflammatory mediator
Figure 6 LC-MS/MS chromatogram of aqueous humor sample showing intraocular penetration of PHF in rabbit eyes. MRM
chromatogram of compounds with high intensity peaks: (1) Quercetin, (2) γ- terpinene, (3) Rosmarinic acid, (4) β-pinene, (5) Dipentene,
(6) Curcumin II.
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http://www.biomedcentral.com/1472-6882/13/1and has been implicated as a probable cause of chronic
ocular inflammation and retinopathy in diabetes [34] and
has also been held responsible for the development and
progression of experimental autoimmune uveitis [35]. Our
study showed that PHF inhibited the formation of LTB4 in
human WBCs while the inhibitory percentage was rela-
tively lower in comparison to zileuton which is a known
lipoxygenase inhibitor.
The widespread prevalence of diabetes in developing
countries is expected to increase the magnitude of blind-
ness due to cataract and the cellular and molecular
mechanisms underlying the pathogenesis of cataract
showed the involvement of polyol pathway, advanced
glycation end products and oxidative stress [36]. The
therapeutic agents that are capable of altering the above
events are expected to prevent or delay the progression
of cataract in order to exhibit the desired anti-cataract
activity e.g. chyavanprash [37]. Considering the major
pathways involved in the etiology of cataract such as
polyol pathway or sorbitol accumulation pathway, antic-
ataract potential of PHF was evaluated using variouspharmacological screening models mimicking the major
pathways in cataract. In the developing chick embryo
model of cataract, glucocorticoid (hydrocortisone) pro-
duced higher incidence (>90%) cataractous changes in
lenses within 48 h [38]. Cataract formation is caused by
oxidative stresses, probably derived from hydrocortisone
effects on the main target organ, the liver and can be
prevented by radical scavengers including ascorbic acid
and insulin. In this model of hyperglycemia and oxida-
tive changes in lens including glutathione depletion are
emphasized as factors for the loss of transparency. The
present study observed a delay in the progression of
cataract in all three models of cataract as compared to
their untreated controls. However, the PHF did not show
any noticeable free radical scavenging activity in the
DPPH assay thereby demarking the presence of any anti-
oxidant potential at the studied concentration. From this
observation, it is evident that the mild anticataract activ-
ity observed with PHF could be beyond its antioxidant
property or as a cumulative effect of antioxidant com-
pounds after repeated administration.
Velpandian et al. BMC Complementary and Alternative Medicine 2013, 13:1 Page 11 of 12
http://www.biomedcentral.com/1472-6882/13/1In order to evaluate the possible intraocular penetration
of PHF, a study was conducted by taking the aqueous
humor after multiple topical instillations for availability
of compounds present in PHF. Information dependent
acquision method was develpoed and used for the test-
ing of the availability of compounds in PHF. Further-
more presence of compounds in PHF was confirmed by
MRM and used for aqueous humor analysis. This study
proved that some of the compounds found in PHF have
the propansity to cross the cornea to produce the
intraocular effects. Among the penetrated compounds
curcumin, rosmarinic acid and quercetin are capable
of having anticataract activity as reported previously
[39-41] whereby curcumin has also been reported for its
antiangiogenic potential [42]. However, further studies
with isolated and purified compounds are essential to
reveal the extent of their penetration for their correl-
ation with observed activity. As the PHF is a proprietary
Ayurvedic formulation having many components with
very low concentrations, the mild but significant pro-
tective effects observed on inflammation, angiogenesis
and cataract can have cumulative and synergestic effects
while on repeated topical applications in patients for
their obvious therapeutic effect with low or no toxicity
as observed in clinical studies.Conclusions
The PHF showed significant antiangiogenic and anti-
inflammatory activities and noticeable anticataract activ-
ity. However, the PHF did not exhibit any antioxidant
potenial and did not show any cytotoxicity against HeLa
cancer cell lines. Moreover, the intraocular penetration
studies revealed that some of the components of PHF
were capable of having transcorneal penetration. The
significant antiangiogenic and anti-inflammatory activ-
ities evinced by the PHF merits further investigation of
PHF for ocular neovascular and inflammatory diseases
in humans.
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